# Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

> **NCT00793546** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 42 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Bosutinib
- **DRUG:** exemestane
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT00793546
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00793546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00793546, "Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00793546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*